Alnylam Granted IDT License to Provide RNAi Products and Services
News Mar 01, 2006
Alnylam Pharmaceuticals, Inc. and Integrated DNA Technologies, Inc. have announced that Alnylam has granted IDT a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family.
This patent family, owned exclusively by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells.
"This agreement with IDT, one of the leading suppliers in the U.S. of DNA and RNA oligonucleotides for research applications, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental IP in the field of RNAi," said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG.
"Alnylam continues to leverage its leading intellectual property estate through relationships that we expect will create value today, and in the future. This brings the number of license agreements Alnylam has executed granting rights to 20, including 11 with research product suppliers."
"We are pleased to be able to strengthen our Dicer-Substrate RNAi product offerings to our customers," said Roman Terrill, General Counsel of IDT.
"Taking a license to the Kreutzer-Limmer patent family reinforces our ability to supply custom RNAi duplexes and our proprietary Trifecta™ kits in the areas of academic research, biotechnology, and pharmaceutical development."
Alnylam's IP estate includes certain 'fundamental' patents and patent applications that claim the broad structural and functional properties of synthetic RNAi products.
These include the Kreutzer-Limmer I and II patents, acquired through the Ribopharma merger: EP Patent No. 1144623, covering methods, medicaments and uses of siRNAs with up to 25 nucleotides complementary to a target gene; EP Patent No. 1214945, covering compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides; and EP Patent No. 1352061, covering therapeutic compositions, methods, and uses of siRNA and derivatives directed toward over 125 disease targets.
Additional fundamental patents licensed to Alnylam on an exclusive or non-exclusive basis include those of Crooke (U.S. Patent Nos. 5,898,031 and 6,107,094), Fire and Mello (U.S. Patent No. 6,506,559), Glover et al. (EP Patent No. 1230375), and the Tuschl II series (derived from WO 02/044321 and including recently allowed claims US 10/832,248 and US 10/832,432, with further patent applications pending).
In addition, Alnylam has licenses to other 'fundamental' patents pending, including Tuschl I (derived from WO 01/075164).
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019